Health brief
Therapeutic Discoveries and Clinical Scale
Israeli researchers leverage real-world health databases for cancer breakthroughs while Sheba plans a massive footprint expansion.
Health
Combining sildenafil with common statins starves migrating cancer cells of cholesterol — offering a cheap, immediately deployable strategy to disrupt tumor metastasis.
BackgroundMetastasis occurs when cancer cells break away from a primary tumor to form new growths in other organs. To power this physical migration, cancer cells rely heavily on internal cholesterol transport systems.
- Sildenafil blocks the PDE5 enzyme to rise cGMP levels, disrupting the cellular machinery that moves cholesterol inside cancer cells.
- Combining the drug with cholesterol-lowering statins cuts off both the internal transport and synthesis of new cholesterol, starvation that prevents cellular migration.
- Analyzing Clalit’s real-world database showed that oncology patients using both medications had directionally higher overall survival rates, offering a cheap repurposing pathway.
Health
Approved plans to double Sheba Medical Center's bed capacity will integrate the hospital into the metro system — transitioning Israel’s largest medical site into an open, transit-connected hub.
BackgroundSheba Medical Center in Tel Hashomer is Israel’s largest hospital and a leading global research institution. Rapid population growth in central Israel has placed severe strain on these existing healthcare facilities.
- The newly approved master plan will nearly double Sheba’s inpatient capacity from 1,860 beds to 3,303 beds by 2045, addressing critical regional shortages.
- Upgrades include two new rooftop helipads, extensive solar arrays, and direct pedestrian integrations with the metro, shifting how patients and staff access the site.
- The layout transitions the historically closed, military-adjacent medical campus into a park-connected public health district, opening the hospital to surrounding neighborhoods.
Health
Clalit's database reveals that daily Vitamin D supplementation nearly doubles treatment-free survival for early-stage leukemia patients — setting up a highly accessible clinical strategy to delay toxic chemotherapy.
BackgroundChronic lymphocytic leukemia is a slow-growing blood cancer where clinicians often adopt a watch-and-wait active surveillance strategy. Delaying the progression of the disease extends the time patients can live healthily without undergoing toxic chemotherapy.
- Patients taking daily Vitamin D for at least six months had a median treatment-free survival of 147 months versus 82 months for non-users, delaying toxic clinical interventions.
- The study controlled for variables like age, gender, and baseline lab parameters, establishing a robust statistical link that isolates Vitamin D's therapeutic impact.
- Researchers believe Vitamin D helps regulate immune system pathways to keep early-stage leukemia cells dormant, providing a non-toxic tool to manage slow-progressing cancers.
Unlock the full brief
Sign in to read every signal, takeaway, and source. Free account — Apple, Google, or email.